Abstract: Disclosed are conjugates including a recognition element covalently bonded to or linked through a linker to a payload. The payload is a pharmaceutical agent (e.g., an antineoplastic agent, anti-infective agent, or anti-inflammatory agent) or a diagnostic agent. Also disclosed are methods of using the conjugates.
Type:
Grant
Filed:
February 11, 2021
Date of Patent:
June 4, 2024
Assignee:
Flagship Pioneering Innovations V, Inc.
Inventors:
Spencer Cory Peck, Steven John Taylor, Elijah Lane Bogart, Devin Forest Reed Doud, Joo Hyun Im, Dervla Tamara Isaac, Jenny Liu, Ferdinand Edward Massari, Robert Walter Myers, John Robert Proudfoot, Cheri Ross, John Patrick Casey, Jr., David Arthur Berry
Abstract: A 4,5-bis(4-chlorophenyl)-2-phenyl-1H-imidazole compound, its synthesis, and its use as an anticancer, anti-inflammatory, and/or antimicrobial agent.
Type:
Grant
Filed:
October 23, 2023
Date of Patent:
June 4, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Amer A. Amer, Antar Ahmed Abdelhamid Ahmed
Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. (In the above, A, B and R, and the like are the same as defined in the description of the invention.
Type:
Grant
Filed:
January 6, 2023
Date of Patent:
June 4, 2024
Assignee:
APTABIO THERAPEUTICS INC.
Inventors:
Soo Jin Lee, Sung Hwan Moon, Sooho Ban, Eunsil Lee, Eun Jung Shin, Yoo-Kyung Goh
Abstract: Chemical compounds that inhibit cancer cell growth are provided. The compounds are heteroarotinoids and derivatives thereof with oxygen, nitrogen or sulfur in chroman systems, tetrahydroquinoline systems, and tetrahydrothiochroman systems.
Type:
Grant
Filed:
February 4, 2021
Date of Patent:
May 28, 2024
Assignee:
THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY
Inventors:
Kenneth Darrell Berlin, Richard A. Bunce, Krishna Kumar Gnanasekaran, Field M. Watts, Jr., Donghua Howard Zhou
Abstract: A medicament with excellent JAK kinase (Janus Kinase) inhibitory activity can be used to prevent, treat and/or improve an autoimmune disease (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus and the like). The present invention also provides a pharmaceutically acceptable composition containing the compound and a method for preparing these compounds.
Type:
Grant
Filed:
September 5, 2019
Date of Patent:
May 28, 2024
Assignees:
INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE, CHINA PARMACEUTICAL UNIVERSITY
Inventors:
Tiantai Zhang, Dayong Zhang, Chengjuan Chen, Yuan Yin, Runan Yu, Lei Shu
Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
Type:
Grant
Filed:
March 30, 2023
Date of Patent:
May 14, 2024
Assignee:
Duke University
Inventors:
Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
Abstract: A 9-(2-hydroxyquinolin-3-yl)-10-(2-hydroxyethyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
November 16, 2023
Date of Patent:
April 30, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
Type:
Grant
Filed:
November 8, 2022
Date of Patent:
April 30, 2024
Assignee:
Ajax Therapeutics, Inc.
Inventors:
Craig E. Masse, Jeremy R. Greenwood, Jiayi Xu, Sayan Mondal, Phani Ghanakota
Abstract: The present invention provides 11-arylcinnolino[2,3-f]phenanthridinium salt compounds and method for producing the same by highly regioselective synthesis of 11-phenylimino[2,3-f]phenanthridin-9-ium salts from 2-azobiaryls and alkenes under catalysis of palladium, through double oxidative C—H coupling of alkenes, to give the polycyclic cinnolinophenanthridinium salts in moderate yields. The reaction mechanism involves ortho C—H olefination of 2-azobiaryls by alkenes, intramolecular aza-Michael addition, ?-hydride elimination, electrophilic palladation followed by intramolecular C—H activation and reductive elimination. The prepared quaternary ammonium salts are candidate materials for solution-processable OLED and bioimaging materials.
Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
Type:
Grant
Filed:
January 13, 2020
Date of Patent:
April 23, 2024
Assignee:
The Global Alliance for TB Drug Development, Inc.
Inventors:
Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
Abstract: Preparation of optionally substituted dihydroisoquinolines. The present invention relates to a process for the preparation of optionally substituted dihydroi-soquinolines of the formula I.
Type:
Grant
Filed:
January 14, 2019
Date of Patent:
April 16, 2024
Assignee:
BASF SE
Inventors:
Bernd Mueller, Michael Rack, Michael Seet, Ana Escribano Cuesta, Jan Klaas Lohmann, Georg Christoph Rudolf, Markus Nett, Rainer Hoffmann
Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
Type:
Grant
Filed:
November 16, 2020
Date of Patent:
April 16, 2024
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
Abstract: Synthetic amino acid-modified polymers and methods of making the same and using the same are disclosed. The synthetic amino acid-modified polymers possess distinct thermosensitive, improved water-erosion resistant, and enhanced mechanical properties, and are suitable of reducing or preventing formation of postoperative tissue adhesions. Additionally, the amino acid-modified polymers can also be used as a vector to deliver pharmaceutically active agents.
Abstract: A compound represented by the following formula (A) has excellent control efficacy against weeds, and shows high safety against useful plants.
Abstract: A medicament for preventive and/or therapeutic treatment of multiple sclerosis, especially a pain accompanying multiple sclerosis such as neuropathic pain, which contains a compound having a P2X4 receptor antagonist activity such as a compound represented by the general formula (IH), or a salt thereof or a hydrate or solvate thereof as an active ingredient.
Type:
Grant
Filed:
April 27, 2017
Date of Patent:
March 5, 2024
Assignees:
NIPPON CHEMIPHAR CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same.
Type:
Grant
Filed:
June 12, 2018
Date of Patent:
February 27, 2024
Assignee:
TREVENA, INC.
Inventors:
Philip Michael Pitis, Robert Eugene Boyd, Tamara Ann Miskowski Daubert, Michael John Hawkins, Guodong Liu, Aimee Crombie Speerschneider
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
Type:
Grant
Filed:
September 24, 2020
Date of Patent:
February 20, 2024
Assignee:
Amgen Inc.
Inventors:
Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, David John Kopecky, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Nobuko Nishimura, Youngsook Shin, Nuria A. Tamayo, John Gordon Allen, Jennifer Rebecca Allen
Abstract: A N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 11, 2023
Date of Patent:
February 13, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer